Get started
Author

Rodrigo Gomes Taboada

Observed names: R. Gomes Taboada, R. Taboada, R.G. Taboada, RG Taboada, Rodrigo G Taboada, Rodrigo G. Taboada, Rodrigo Taboada
Institution: AC Camargo Hospital
Observed institution: AC Camargo Hospital
ORCID: 0000-0001-5674-2669
Observed ORCID: 0000-0001-5674-2669
OpenAlex ID: A5076007677
Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms
2022 · Rodrigo Taboada, Laura Claro, et al. · Journal of Neuroendocrinology · 27
Therapy Sequencing in Patients With Advanced Neuroendocrine Neoplasms
2023 · Rachel P. Riechelmann, Rodrigo G. Taboada, et al. · American Society of Clinical Oncology Educational Book · 24
PDF
Disease-Free Survival and Time to Complete Response After Definitive Chemoradiotherapy for Squamous-Cell Carcinoma of the Anus According to HIV Infection
2020 · Marcos Pedro Guedes Camandaroba, Soledad Iseas, et al. · Clinical Colorectal Cancer · 13
HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
2023 · Milton J. Barros, Jonathan Strosberg, et al. · Therapeutic Advances in Medical Oncology · 12
PDF
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
2021 · Melissa Frizziero, Alice Durand, et al. · Cancers · 12
PDF
Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review
2024 · Rodrigo G. Taboada, Felicia P. Cavalher, et al. · Therapeutic Advances in Medical Oncology · 11
Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
2022 · Rodrigo G Taboada, Rachel P Riechelmann, et al. · The Oncologist · 11
PDF
The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors
2024 · Rodrigo G Taboada, Angelo B Brito, et al. · Cancers · 6
PDF
The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer
2022 · Rachel P. Riechelmann, Virgilio S. Silva, et al. · Current Cancer Drug Targets · 6
1154P Prospective multinational evaluation of alkylating-induced hypermutation in neuroendocrine neoplasms (NEN): Clinical and molecular profiles associated with response to immune checkpoint inhibitors (CPI)
2024 · E. Trevisani, S. Cingarlini, et al. · Annals of Oncology · 4
PDF
Survival trends in gastric cancer in Brazil: real-life data from a large cancer center
2024 · Angelo Borsarelli Carvalho Brito, Tiago Cordeiro Felismino, et al. · ecancermedicalscience · 4
oss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer
2024 · Álvaro M C Caldas, Warley A Nunes, et al. · ecancermedicalscience · 4
PDF
Differentiating high-grade neuroendocrine neoplasms
2024 · Rodrigo Gomes Taboada, Rachel P. Riechelmann · Nature reviews. Cancer · 4
Alkylating-induced hypermutation in pancreatic neuroendocrine tumours
2025 · Rodrigo G Taboada, Giovana T Torrezan, et al. · BMJ Oncology · 3
PDF
353P Loss of CDX2 and high COX2 (PTGS2) expression in stage IV colorectal cancer
2022 · A.M.D.C. Caldas, W.A. Nunes, et al. · Annals of Oncology · 2
Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Report and Literature Review
2025 · Rodrigo Gomes Taboada, Maria Fernanda Arruda Almeida, et al. · Journal of Gastrointestinal Cancer · 1
Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)
2020 · Elisa Zaninotto, Melissa Frizziero, et al. · Research Explorer (The University of Manchester) · 1
Timing to achieve complete response (CR) after definitive chemoradiotherapy (ChRT) in patients with squamous cell carcinoma of the anal (SCCAC) with and without HIV infection: A multicenter retrospective study
2019 · M.P.G. Camandaroba, S. Iseas, et al. · Annals of Oncology · 1
Advancing Precision Oncology: Functional Tumoroid Models Predict Therapeutic Response in Gastrointestinal and Pancreatic Cancers
2026 · Tiago Góss dos Santos, Luciana Harumi Osaki, et al. · Brazilian Journal of Oncology
Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors
2026 · G.R. de Almeida, R.P. Riechelmann, et al. · ESMO Gastrointestinal Oncology
PDF
Neoadjuvant radiotherapy after chemotherapy does not improve surgical or survival outcomes in borderline resectable pancreatic cancer
2026 · Larissa Garcia, Guilherme Rossato, et al. · Journal of Gastrointestinal Oncology
165P Early bevacizumab discontinuation (EBD) does not impact outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab (AB)
2025 · D.D.A. Carvalho, T. Felismino, et al. · Annals of Oncology
Efficacy and safety of atezolizumab and bevacizumab in real-world treatment of advanced hepatocellular carcinoma: experience from a cancer center in Brazil
2025 · Daniela de Almeida Carvalho, Angelo Borsarelli Carvalho Brito, et al. · Brazilian Journal of Oncology
Abstract B032: Expanding the geographic reach of functional precision oncology through prediction of therapy response with patient-derived tumoroids
2025 · Luciana Harumi Osaki, Tiago Goss dos Santos, et al. · Cancer Research
Workup of Newly Diagnosed NENs
2025 · Rodrigo Gomes Taboada, Mauro Daniel Spina Donadio, et al. · Endocrinology
Works count: 38
Citation count: 146
H-index: 7
I10-index: 7
Year
Topic
Type